Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

API Manufacturing: SOP for Handling of Returned Drug Product – V 2.0

Posted on By

API Manufacturing: SOP for Handling of Returned Drug Product – V 2.0

Standard Operating Procedure for Handling of Returned Drug Product in API Manufacturing

Department API Manufacturing
SOP No. SOP/API/178/2025
Supersedes SOP/API/178/2022
Page No. Page 1 of 14
Issue Date 14/04/2025
Effective Date 16/04/2025
Review Date 14/04/2026

1. Purpose

To establish a standardized procedure for the receipt, inspection, evaluation, disposition, and documentation of returned drug products in the API manufacturing facility, ensuring traceability and regulatory compliance as per GMP guidelines.

2. Scope

This SOP applies to all finished API batches or intermediate products returned from customers, distributors, or other facilities. It includes procedures for return evaluation,

reprocessing, destruction, and record management.

3. Responsibilities

  • Warehouse Staff: Receive returned product and initiate documentation.
  • QA Officer/Executive: Conduct visual inspection, initiate investigation, and coordinate evaluation.
  • QC Department: Perform required testing on returned samples, if necessary.
  • Head – QA: Make final disposition decision (e.g., reprocess, destroy, or release).
  • Customer Service: Provide reason for return, handling instructions, and customer communication records.
See also  API Manufacturing: SOP for Handling Deviations and Incident Reports - V 2.0

4. Accountability

The Head of QA is accountable for ensuring that all returned drug products are handled in accordance with applicable regulations, product integrity standards, and company policies.

5. Procedure

5.1 Receipt of Returned Drug Product

  1. Upon arrival of returned product, Warehouse staff shall:
    • Verify transport documentation
    • Segregate the product from usable stock
    • Label clearly as “Returned Material – Quarantine”
    • Initiate Return Receipt Form (Annexure-1)

5.2 Documentation Requirements

  1. QA shall ensure the following information is collected:
    • Product name, batch number, quantity returned
    • Reason for return (damage, expiry, quality issue, temperature deviation)
    • Customer complaint or communication details
    • Transport and storage conditions during return

5.3 Visual and Preliminary Inspection

  1. QA shall perform visual inspection of returned containers for:
    • Seal integrity
    • Label condition
    • Physical damage
    • Cross-contamination risk
  2. Record observations in Return Evaluation Form (Annexure-2).

5.4 Evaluation and Risk Assessment

  1. QA, in coordination with QC and Production, shall evaluate:
    • Stability concerns due to environmental exposure
    • Possibility of contamination or mix-up
    • Retention samples comparison (if available)
    • Need for reanalysis or reprocessing
  2. QC may test returned samples for assay, impurities, moisture, and microbial count if required.

5.5 Disposition Decision

  1. Based on findings, QA Head shall decide whether:
    • The product is suitable for reprocessing
    • The product may be returned to stock (in rare cases)
    • The product must be destroyed
  2. Record the final disposition decision in Disposition Form (Annexure-3).
See also  API Manufacturing: SOP for Handling Discrepant IPC Observations - V 2.0

5.6 Handling of Approved Returns

  1. If returned product is suitable for reprocessing:
    • Initiate batch reprocessing protocol
    • Revise BMR accordingly
    • Retest and release via QA as per reprocessing SOP
  2. All steps must be approved before execution.

5.7 Handling of Rejected Returns

  1. If product is rejected:
    • Label as “To Be Destroyed”
    • Transfer to rejection area
    • Destroy as per site destruction SOP with QA witness
  2. Destruction details must be entered in the Destruction Log (Annexure-4).

5.8 Record Keeping and Trending

  1. All returned product records must be maintained for at least 5 years.
  2. QA shall compile quarterly return summary reports (Annexure-5) including:
    • Number of returns
    • Return reasons
    • Disposition trends
  3. Discussed during management review and APQR.

6. Abbreviations

  • QA: Quality Assurance
  • QC: Quality Control
  • BMR: Batch Manufacturing Record
  • APQR: Annual Product Quality Review

7. Documents

  1. Return Receipt Form (Annexure-1)
  2. Return Evaluation Form (Annexure-2)
  3. Disposition Form (Annexure-3)
  4. Destruction Log (Annexure-4)
  5. Quarterly Return Summary Report (Annexure-5)
See also  API Manufacturing: SOP for Quality Risk Management using FMEA - V 2.0

8. References

  • 21 CFR 211.204 – Returned Drug Products
  • ICH Q10 – Pharmaceutical Quality System
  • EU GMP Part I – Chapter 8 (Complaints and Product Recall)

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Return Receipt Form

Date Product Batch No. Qty Returned Customer Reason
12/04/2025 API-X AXB2025 25 kg Client A Seal damage

Annexure-2: Return Evaluation Form

Parameter Observation Remarks
Seal Condition Intact Acceptable
Labeling Clear Legible
Container Damage None OK

Annexure-3: Disposition Form

Batch No. Disposition QA Decision Date
AXB2025 Reprocess Approved 13/04/2025

Annexure-4: Destruction Log

Date Batch No. Qty Destroyed Method Witness
14/04/2025 AXC2025 10 kg Incineration QA Officer

Annexure-5: Quarterly Return Summary Report

Quarter Total Returns Major Reasons % Reprocessed % Destroyed
Q1 2025 4 Seal leakage, Label smudge 50% 50%

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial SOP New document QA Head
14/04/2025 2.0 Added return summary reporting and destruction log Process improvement QA Head
API Manufacturing V 2.0 Tags:API batch record, API BMR, API calibration, API centrifuge, API cleaning, API crystallization, API deviation, API documentation, API drying, API equipment cleaning, API filtration, API GMP compliance, API granulation, API hold time, API impurities, API line clearance, API manufacturing, API process, API quality control, API reactor, API sampling, API solvent handling, API validation, API waste disposal, API yield

Post navigation

Previous Post: BA-BE Studies: SOP for Column Performance Qualification – V 2.0
Next Post: Analytical Method Development: Morphology Assessment SOP – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version